Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Up – What’s Next?

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) gapped up prior to trading on Tuesday . The stock had previously closed at $18.33, but opened at $19.39. Kestra Medical Technologies shares last traded at $19.0050, with a volume of 62,765 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KMTS. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. BTIG Research restated a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research report on Wednesday, March 25th. Piper Sandler raised their price target on Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. The Goldman Sachs Group set a $24.00 price objective on shares of Kestra Medical Technologies in a research note on Friday, January 16th. Finally, Stifel Nicolaus set a $30.00 target price on Kestra Medical Technologies in a research note on Friday, December 12th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.80.

Kestra Medical Technologies Trading Up 0.6%

The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15. The firm has a 50 day moving average price of $23.45 and a two-hundred day moving average price of $24.67. The company has a market cap of $1.17 billion and a price-to-earnings ratio of -5.06.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The firm had revenue of $24.55 million during the quarter. The business’s quarterly revenue was up 62.7% on a year-over-year basis.

Insiders Place Their Bets

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $20.27, for a total value of $304,050.00. Following the transaction, the insider directly owned 364,786 shares of the company’s stock, valued at approximately $7,394,212.22. The trade was a 3.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 45,000 shares of company stock valued at $1,030,050 in the last ninety days. Insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Several institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC bought a new stake in Kestra Medical Technologies in the 4th quarter valued at about $31,000. Russell Investments Group Ltd. increased its stake in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Kestra Medical Technologies during the third quarter valued at approximately $48,000. BNP Paribas Financial Markets increased its position in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares during the last quarter. Finally, Daiwa Securities Group Inc. bought a new stake in Kestra Medical Technologies in the fourth quarter worth about $72,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.